Brief: Autolus Therapeutics Announces Pivotal Phase 2 Felix Clinical Trial Has Met Primary Endpoint At Interim Analysis
08/12/2022 21:28
Dec 8 (Reuters) - Autolus Therapeutics PLC AUTL.O :
* AUTOLUS THERAPEUTICS ANNOUNCES PIVOTAL PHASE 2 FELIX
CLINICAL
TRIAL HAS MET PRIMARY ENDPOINT AT INTERIM ANALYSIS
* AUTOLUS THERAPEUTICS PLC- ADULT ACUTE LYMPHOBLASTIC
LEUKEMIA
(ALL) HAS MET ITS PRIMARY ENDPOINT
* AUTOLUS THERAPEUTICS PLC - ACHIEVEMENT OF DEVELOPMENT
MILESTONE
HAS TRIGGERED PAYMENT OF $35M FROM BLACKSTONE LIFE SCIENCES
* AUTOLUS THERAPEUTICS PLC- WORK TOWARDS SUBMISSION OF A
BIOLOGICS
LICENSE APPLICATION (BLA) BY END OF 2023 TO U.S. FOOD AND DRUG
ADMINISTRATION
Source text for Eikon: ID:nGNXypnLL
Further company coverage: AUTL.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Autolus Therapeutics
See all newsBrief: Autolus Therapeutics PLC Unit Enters Master Service Agreement With AGC Biologics
Brief: Autolus Therapeutics Appoints Ryan Richardson To Board Of Directors
Brief: Nice Recommends Aucatzyl As A Treatment Option For Adult Patients With Lymphoblastic Leukemia
Brief: Autolus Therapeutics’ Car T Therapy Aucatzyl® (Obecabtagene Autoleucel) Granted European Marketing Authorization For Adult Patients
Brief: Autolus Therapeutics Announces Inducement Grants